Transforming Growth Factor-β2 and Connective Tissue Growth Factor in Proliferative Vitreoretinal Diseases
Transforming Growth Factor-β2 and Connective Tissue Growth Factor in Proliferative Vitreoretinal Diseases Possible Involvement of Hyalocytes and Therapeutic Potential of Rho Kinase Inhibitor Takeshi Kita 1 , Yasuaki Hata 1 , Kumiko Kano 1 , Muneki Miura 1 , Shintaro Nakao 1 , Yoshihiro Noda 1 , Hiro...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 56; no. 1; pp. 231 - 238 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Diabetes Association
01.01.2007
|
Online Access | Get full text |
Cover
Loading…
Summary: | Transforming Growth Factor-β2 and Connective Tissue Growth Factor in Proliferative Vitreoretinal Diseases
Possible Involvement of Hyalocytes and Therapeutic Potential of Rho Kinase Inhibitor
Takeshi Kita 1 ,
Yasuaki Hata 1 ,
Kumiko Kano 1 ,
Muneki Miura 1 ,
Shintaro Nakao 1 ,
Yoshihiro Noda 1 ,
Hiroaki Shimokawa 2 and
Tatsuro Ishibashi 1
1 Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 Department of Cardiology, Graduate School of Medicine, Tohoku University, Miyagi, Japan
Address correspondence and reprint requests to Yasuaki Hata, MD, PhD, Department of Ophthalmology, Graduate School of Medical
Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan. E-mail: hatachan{at}med.kyushu-u.ac.jp
Abstract
The critical association of connective tissue growth factor (CTGF), which is thought to be one of the downstream mediators
of transforming growth factor-β (TGF-β), with vitreoretinal diseases remains to be clarified. In the current study, we first
demonstrated the correlation between the concentrations of TGF-β2 as well as CTGF in the vitreous and CTGF gene regulation
in cultured hyalocytes. Concentrations of TGF-β2 and CTGF in the vitreous from patients with proliferative vitreoretinal diseases
were significantly higher than in those with nonproliferative diseases, and there was a positive correlation between their
concentrations ( r = 0.320, P < 0.01). Cultured hyalocytes expressed CTGF mRNA, which was enhanced in the presence of TGF-β2, associated with nuclear accumulation
of Smad4. TGF-β2–dependent Smad4 translocation and CTGF gene expression were mediated through Rho kinase and at least partially
via p38 mitogen-activated protein kinase. Finally, fasudil, a Rho kinase inhibitor already in clinical use, inhibited both
Smad4 translocation and CTGF gene expression. In conclusion, combined effects of TGF-β2 and CTGF appear to be involved in
the pathogenesis of proliferative vitreoretinal diseases. Hyalocytes may be a possible source of CTGF and thus might play
a role in vitreoretinal interface diseases. Furthermore, Rho kinase inhibitors might have therapeutic potential to control
fibrotic disorders in the eye.
CTGF, connective tissue growth factor
DMEM, Dulbecco’s modified Eagle’s medium
MAPK, mitogen-activated protein kinase
PDR, proliferative diabetic retinopathy
PVR, proliferative vitreoretinopathy
RRD, rhegmatogenous retinal detachment
TGF-β, transforming growth factor-β
Footnotes
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted August 22, 2006.
Received April 29, 2006.
DIABETES |
---|---|
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/db06-0581 |